Jennifer Lloyd, Nazy Zomorodian, Geeta Devgan, Julia Batten
{"title":"Talazoparib 加 Enzalutamide 用于 HRR 缺乏的 mCRPC 患者：肿瘤科护士和高级执业医师的实用实施步骤》。","authors":"Jennifer Lloyd, Nazy Zomorodian, Geeta Devgan, Julia Batten","doi":"10.1188/24.CJON.483-491","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>About one-quarter of patients with advanced prostate cancer have alterations in homologous recombination repair (HRR) genes. In a global phase 3 study, talazoparib plus enzalutamide significantly improved progression-free survival in patients with HRR-deficient metastatic castration-resistant prostate cancer (mCRPC).</p><p><strong>Objectives: </strong>This article reviews the role of oncology nurses and advanced practice providers (APPs) in administering talazoparib plus enzalutamide in patients with mCRPC.</p><p><strong>Methods: </strong>This review and hypothetical case study illustrate the role of oncology nurses and APPs in the administration of talazoparib plus enzalutamide and the management of adverse events to ensure safe and effective use in clinical practice.</p><p><strong>Findings: </strong>Oncology nurses and APPs play an important role in the dosing and administration of talazoparib plus enzalutamide and can recognize and manage adverse events in patients with HRR-deficient mCRPC.</p>","PeriodicalId":10350,"journal":{"name":"Clinical journal of oncology nursing","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology Nurses and Advanced Practice Providers.\",\"authors\":\"Jennifer Lloyd, Nazy Zomorodian, Geeta Devgan, Julia Batten\",\"doi\":\"10.1188/24.CJON.483-491\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>About one-quarter of patients with advanced prostate cancer have alterations in homologous recombination repair (HRR) genes. In a global phase 3 study, talazoparib plus enzalutamide significantly improved progression-free survival in patients with HRR-deficient metastatic castration-resistant prostate cancer (mCRPC).</p><p><strong>Objectives: </strong>This article reviews the role of oncology nurses and advanced practice providers (APPs) in administering talazoparib plus enzalutamide in patients with mCRPC.</p><p><strong>Methods: </strong>This review and hypothetical case study illustrate the role of oncology nurses and APPs in the administration of talazoparib plus enzalutamide and the management of adverse events to ensure safe and effective use in clinical practice.</p><p><strong>Findings: </strong>Oncology nurses and APPs play an important role in the dosing and administration of talazoparib plus enzalutamide and can recognize and manage adverse events in patients with HRR-deficient mCRPC.</p>\",\"PeriodicalId\":10350,\"journal\":{\"name\":\"Clinical journal of oncology nursing\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical journal of oncology nursing\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1188/24.CJON.483-491\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"NURSING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical journal of oncology nursing","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1188/24.CJON.483-491","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NURSING","Score":null,"Total":0}
Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology Nurses and Advanced Practice Providers.
Background: About one-quarter of patients with advanced prostate cancer have alterations in homologous recombination repair (HRR) genes. In a global phase 3 study, talazoparib plus enzalutamide significantly improved progression-free survival in patients with HRR-deficient metastatic castration-resistant prostate cancer (mCRPC).
Objectives: This article reviews the role of oncology nurses and advanced practice providers (APPs) in administering talazoparib plus enzalutamide in patients with mCRPC.
Methods: This review and hypothetical case study illustrate the role of oncology nurses and APPs in the administration of talazoparib plus enzalutamide and the management of adverse events to ensure safe and effective use in clinical practice.
Findings: Oncology nurses and APPs play an important role in the dosing and administration of talazoparib plus enzalutamide and can recognize and manage adverse events in patients with HRR-deficient mCRPC.
期刊介绍：
The Clinical Journal of Oncology Nursing (CJON) is an official publication of the Oncology Nursing Society (ONS) and is directed to the practicing nurse specializing in the care of patients with an actual or potential diagnosis of cancer. CJON is a vehicle to promote the mission of ONS, which is to advance excellence in oncology nursing and quality cancer care. The CJON mission is twofold: to provide practical information necessary to care for patients and their families across the cancer continuum and to develop publication skills in oncology nurses.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
